Main Article Content


Endometrial cancer (EC) is the most common gynaecological cancer. The combination of lenvatinib and pembrolizumab has exhibited efficacy as the second line treatment for advanced EC, with a significant benefit in terms of progression free survival (PFS) and overall survival, but the adverse events (AE) profile is complex. AEs associated with the treatment may represent a limitation to this combination. Here, we report the case of a 38-year-old female patient diagnosed with stage IV EC elsewhere, whose disease progressed after the first line of treatment and was referred to a specialised cacncer centre in Muscat, Oman, in 2021. We treated her with the combination of lenvatinib and pembrolizumab. During the course of the treatment, she developed hand-foot syndrome grade III and hypothyroidism grade II. The AEs were managed with supportive medications, dose interruptions, dose reductions and multidisciplinary care, which allowed the continuation of the treatment. The patient achieved a good partial response and an ongoing PFS of more than 12 months.

Keywords: Cancer; Endometrial Cancer; Lenvatinib; Pembrolizumab; Adverse Drug Events; Hand-Foot Syndrome; Hypothyroidism; Oman.

Article Details

How to Cite
Zribi, A., Al Riyami, K., Al Zahibi, H. S., & Burney, I. A. (2024). Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer. Sultan Qaboos University Medical Journal, 24(2), 293–297.

Most read articles by the same author(s)

1 2 > >>